US to procure 3.2 million doses of Covid-19 vaccine from Novavax
Pharmaceutical Technology
JULY 12, 2022
A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain. It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.
Let's personalize your content